Stockscreener 앱 받기
17.85
1.05%
-0.19
시간 외 거래:
17.85
전일 마감가:
$18.04
열려 있는:
$17.8605
하루 거래량:
2.12M
Relative Volume:
1.12
시가총액:
$5.70B
수익:
$3.05B
순이익/손실:
$181.32M
주가수익비율:
47.86
EPS:
0.373
순현금흐름:
$186.11M
1주 성능:
+4.94%
1개월 성능:
+9.64%
6개월 성능:
+33.11%
1년 성능:
+116.63%
1일 변동 폭
$17.82
$18.39
1주일 범위
$16.58
$18.39
52주 변동 폭
$7.665
$18.39
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
명칭
Amneal Pharmaceuticals Inc
전화
908-947-3120
주소
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
17.85 | 5.76B | 3.05B | 181.32M | 186.11M | 0.373 |
TAK
Takeda Pharmaceutical Co Adr
|
17.15 | 53.43B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
10.10 | 44.52B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.03 | 37.52B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.56 | 32.24B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
535.67 | 22.46B | 3.17B | 1.29B | 1.01B | 27.09 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-17 | 개시 | UBS | Buy |
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-06-06 | 개시 | Goldman | Buy |
| 2025-02-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-09-06 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | 업그레이드 | Goldman | Sell → Buy |
| 2020-12-14 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2020-12-14 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-07-27 | 개시 | Goldman | Sell |
| 2020-05-12 | 업그레이드 | Guggenheim | Sell → Neutral |
| 2019-12-12 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-11-07 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | 개시 | Barclays | Equal Weight |
| 2019-05-21 | 업그레이드 | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | 개시 | SunTrust | Buy |
| 2019-03-08 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | 다운그레이드 | SunTrust | Buy → Hold |
| 2018-08-13 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | 개시 | Morgan Stanley | Overweight |
| 2018-06-22 | 개시 | B. Riley FBR, Inc. | Buy |
모두보기
Amneal Pharmaceuticals Inc 주식(AMRX)의 최신 뉴스
Amneal Pharmaceuticals (AMRX) Proxy filing Summary - Quartr
Amneal receives FDA approval for additional iohexol strengths - Investing.com
Amneal Pharmaceuticals Receives FDA Approval for Additional Iohexol Injection Strengths and Vial Presentations - Quiver Quantitative
Amneal receives FDA approval for additional iohexol strengths By Investing.com - Investing.com Canada
Amneal's FDA-approved contrast options give hospitals more vial choices - Stock Titan
Amneal gains FDA approval for four iohexol products - grafa.com
Amneal Pharmaceuticals stock hits 52-week high at 17.86 USD By Investing.com - Investing.com South Africa
Amneal Pharmaceuticals stock hits 52-week high at 17.86 USD - Investing.com
Amneal Pharmaceuticals (AMRX) Barclays 28th Annual Global Healthcare Conference summary - Quartr
Amneal Pharmaceuticals stock holds steady as generic pipeline supports long term growth - Ad-hoc-news.de
Amneal schedules July 30 call for second-quarter 2026 results - Stock Titan
Amneal to Report Second Quarter 2026 Results on July 30, 2026 - The Manila Times
Amneals Planned Sterile Facility Creates Opportunity For Aseptic Filling Isolator And Automation Suppliers - Pharmaceutical Online
Enterprise value to revenue forward of Amneal Pharmaceuticals, Inc. – NASDAQ:AMRX - TradingView
Generic Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs Peers - Yahoo Finance
Amneal Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Kiely John - Moomoo
Did EMA’s Positive Hopledo Ruling Just Shift Amneal Pharmaceuticals' (AMRX) Investment Narrative? - Sahm
Amneal Sues Alembic to Block Copies of Crexont Parkinson’s Drug - Bloomberg Law News
Amneal Pharmaceuticals updates investors on its generics and specialty pipeline. The company focuses - ad-hoc-news.de
$2M from Amneal targets Parkinson's drug costs for patients - Stock Titan
Amneal Pharmaceuticals (AMRX) Gets EU Backing For Hopledo, Is It Fully Priced? - Sahm
Price to sales forward of Amneal Pharmaceuticals, Inc. – NASDAQ:AMRX - TradingView
Amneal Pharmaceuticals : New U.S. Sterile Manufacturing Facility Selected for FDA PreCheck Pilot Program - marketscreener.com
Price to book forward of Amneal Pharmaceuticals, Inc. – NASDAQ:AMRX - TradingView
Price to earnings forward of Amneal Pharmaceuticals, Inc. – NASDAQ:AMRX - TradingView
Eli Lilly, Regeneron Join FDA Pilot Designed To Accelerate US Manufacturing Readiness - Sahm
Lilly, Regeneron selected for US program to review new manufacturing plants faster - Reuters
Amneal to Buy Kashiv for $375M Cash + 28.9M Shares (NASDAQ: AMRX) - Stock Titan
EMA Recommends Approval of Hopledo for Parkinson's Disease - Intellectia AI
Zambon and Amneal Receive Positive CHMP Opinion for Hopledo in Parkinson’s Disease in Europe - Quiver Quantitative
Does Amneal (AMRX) Joining Three Russell 2000 Defensive Indexes Recast Its Risk Profile? - simplywall.st
Amneal Pharmaceuticals, Inc.(NasdaqGS:AMRX) added to Russell 2000 Value-Defensive Index - marketscreener.com
Amneal Pharmaceuticals, Inc.(NasdaqGS:AMRX) added to Russell 2000 Growth-Defensive Index - marketscreener.com
Amneal Pharmaceuticals, Inc.(NasdaqGS: AMRX) added to Russell 2000 Defensive Index - marketscreener.com
Form DEF 14A Amneal Pharmaceuticals Inc Class A For: 26 June - Investing.com UK
2DT Forecast — Price Target — Prediction for 2027 - TradingView
Amneal Pharmaceuticals, Inc. Class A Actuals & Estimates (NASDAQ:AMRX) - TradingView
AMRX Forecast — Price Target — Prediction for 2027 - TradingView
Amneal Pharmaceuticals (AMRX) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
Amneal Pharmaceuticals advances after securing FDA clearance for cancer treatment (AMRX) - MSN
Amneal Pharmaceuticals stock hits 52-week high at 16.62 USD - Investing.com
Amneal Pharmaceuticals stock hits 52-week high at 16.62 USD By Investing.com - Investing.com South Africa
Rytvela from Amneal Pharmaceuticals Inc.biosimilar for chronic uveitis care - AD HOC NEWS
Amgen Inc. v. Amneal Pharm. LLC United States Court of Appeals of the Federal Circuit, 2020 945 F.3d 1368, 2020 - Sage Journals
Amneal Pharmaceuticals (AMRX) Stock Could Be 6% Below Fair Value After Its Sharp Rally - Sahm
Amneal (AMRX) agrees to buy Kashiv for $375M cash plus equity and milestones - Stock Titan
Amneal Pharmaceuticals Inc (AMRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Amneal Pharmaceuticals Inc (AMRX) Institutional Confidence - TradingKey
Amneal Pharmaceuticals Inc (AMRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Amneal Pharmaceuticals Inc (AMRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Amneal Pharmaceuticals Inc - TradingKey
Amneal Pharmaceuticals Inc (AMRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.50%
0.79%
자본화:
|
볼륨(24시간):